

DERMATOLOGY REFERRAL FORM

Y Medical Associates
Fax: 855-838-0623
Phone: 800-447-7558



Date: _____

Patient Information

Patient Name: _____
 Address: _____
 City, State, Zip: _____
 Home Phone: _____
 Cell Phone: _____
 DOB: _____
 Gender: M F

Prescriber Information

Prescriber Name: _____
 Address: _____
 City, State, Zip: _____
 Phone: _____
 Fax: _____
 DEA: _____ NPI #: _____
 Contact Person: _____

Insurance Information

Primary Insurance: _____ ID#: _____ Group: _____
 Secondary Insurance: _____ ID#: _____ Group: _____
 Prescription Card: _____ ID#: _____ BIN#: _____ PCN#: _____ Group: _____

Clinical Information (please fax all pertinent clinical information)


Diagnosis: L20.9 (Atopic Dermatitis) L40.0 (Psoriasis Vulgaris/Plaque Psoriasis/Nummular Psoriasis) L40.8 (Other Psoriasis)
 L40.9 (Psoriasis/Unspecified) L40.5 (Psoriatic Arthritis) L73.2 (Hidradenitis Suppurativa)
 M33 (Dermatopolymyositis) M33.1 (Dermatomyositis) L12.9 (Pemphigoid/Pemphigus) L10.0 (Pemphigus Vulgaris)
 Diagnosis Date: _____ Height: _____ Weight: _____ Tb Test: Yes No Neg. Text Date: _____
 HBV: Yes No If Yes, Currently Treated: Yes No Allergies: _____
 BSA Affected (%): _____ Affected Areas: Palms Soles Head Neck Genitalia _____
 Prior Therapy: Yes No Reason for Discontinuation of Therapy: _____
 Approximate Start Date: _____ Approximate End Date: _____

Prescription Information

Medication	Dose Strength	Directions	Qty	Refills
Cimzia	<input type="checkbox"/> 6 x 200mg/mL (PFS Starter Kit) <input type="checkbox"/> 2 x 200mg/mL PFS <input type="checkbox"/> 2 x 200mg/mL Vial	<input type="checkbox"/> Inject 400mg SC at weeks 0, 2 and 4 <input type="checkbox"/> Inject 200mg SC every 2 weeks <input type="checkbox"/> Inject 400mg SC every 4 weeks <input type="checkbox"/> For some patients <90kg: Inject 400mg SC at weeks 0, 2 and 4, then 200mg every 2 weeks		
Cosentyx	<input type="checkbox"/> 300mg Sensoready Pen <input type="checkbox"/> 150mg Sensoready Pen	<input type="checkbox"/> Starter Dose: Inject SC weeks 0, 1, 2, 3, and 4 <input type="checkbox"/> Maintenance Dose: Inject SC every 4 weeks		
Dupixent	<input type="checkbox"/> 300mg PFS <input type="checkbox"/> 200mg PFS	<input type="checkbox"/> Starter Dose: Inject 200mg SC on Day 1 and Day 15 <input type="checkbox"/> Starter Dose: Inject 300mg SC on Day 1 and Day 15 <input type="checkbox"/> Maintenance Dose: Inject 200mg SC every 2 weeks thereafter <input type="checkbox"/> Maintenance Dose: Inject 300mg SC every 2 weeks thereafter		
Enbrel	<input type="checkbox"/> 50mg/mL Prefilled Syringe <input type="checkbox"/> 50mg/mL SureClick Autoinjector <input type="checkbox"/> 25mg/0.5mL Prefilled Syringe	<input type="checkbox"/> Starter Dose: Inject 50mg SC twice a week (72-96 hours apart for 3 months) <input type="checkbox"/> Maintenance Dose: Inject SC every 4 weeks		
Humira	<input type="checkbox"/> 20mg/0.2mL Pen <input type="checkbox"/> 40mg/0.4mL Pen <input type="checkbox"/> 40mg/0.8mL Pen or Syringe <input type="checkbox"/> 40mg Kit 4 x 0.8mL <input type="checkbox"/> 40mg Psoriasis Starter Pack	<input type="checkbox"/> Starter Dose: Inject 80mg SC on Day 1 <input type="checkbox"/> Maintenance Dose: Inject 40mg SC once weekly thereafter Other: _____	<input type="checkbox"/> Initial Dose 1: Other: _____ <input type="checkbox"/> Injection training required from my Humira	
Ilumya	<input type="checkbox"/> 100mg/mL Prefilled Syringe	<input type="checkbox"/> Starter Dose: Inject 100mg SC at weeks 0 and 4 <input type="checkbox"/> Maintenance Dose: 100mg SC every 12 weeks		

Prescriber Signature: _____ DAW (Dispense as Written) Date: _____

The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intend recipient, please notify us immediately.

DERMATOLOGY REFERRAL FORM	Y Medical Associates Fax: 855-838-0623 Phone: 800-447-7558	
Date: _____		

Patient Information	Prescriber Information
Patient Name: _____ Address: _____ City, State, Zip: _____ Home Phone: _____ Cell Phone: _____ DOB: _____ Gender: <input type="checkbox"/> M <input type="checkbox"/> F	Prescriber Name: _____ Address: _____ City, State, Zip: _____ Phone: _____ Fax: _____ DEA: _____ NPI #: _____ Contact Person: _____


Insurance Information		
Primary Insurance: _____	ID#: _____	Group: _____
Secondary Insurance: _____	ID#: _____	Group: _____
Prescription Card: _____	ID#: _____	BIN#: _____ PCN#: _____ Group: _____

Clinical Information (please fax all pertinent clinical information)	
Diagnosis: <input type="checkbox"/> L20.9 (Atopic Dermatitis) <input type="checkbox"/> L40.0 (Psoriasis Vulgaris/Plaque Psoriasis/Nummular Psoriasis) <input type="checkbox"/> L40.8 (Other Psoriasis) <input type="checkbox"/> L40.9 (Psoriasis/Unspecified) <input type="checkbox"/> L40.5 (Psoriatic) <input type="checkbox"/> L73.2 (Hidradenitis Suppurativa)	
Arthritis <input type="checkbox"/> M33 (Dermatopolymyositis) <input type="checkbox"/> M33.1 (Dermatomyositis) <input type="checkbox"/> 2.9 (Pemphigoid/Pemphigus) <input type="checkbox"/> L10.0 (Pemphigus Vulgaris)	
Diagnosis Date: _____ Height: _____ Weight: _____ Tb Test: <input type="checkbox"/> Yes <input type="checkbox"/> No Neg. Text Date: _____	
HBV: <input type="checkbox"/> Yes <input type="checkbox"/> No If Yes, Currently Treated: <input type="checkbox"/> Yes <input type="checkbox"/> No Allergies: _____	
BSA Affected (%): _____ Affected Areas: <input type="checkbox"/> Palms <input type="checkbox"/> Soles <input type="checkbox"/> Head <input type="checkbox"/> Neck <input type="checkbox"/> Genitalia <input type="checkbox"/> _____	
Prior Therapy: <input type="checkbox"/> Yes <input type="checkbox"/> No Reason for Discontinuation of Therapy: _____	
Approximate Start Date: _____ Approximate End Date: _____	

Prescription Information				
Medication	Dose Strength	Directions	Qty	Refills
IVIG Orders		_____ mg/kg IV divided over _____ day(s) _____ mg/kg IV divided over _____ day(s) Frequency: <input type="checkbox"/> Every _____ weeks for one year <input type="checkbox"/> one time dose		
Orencia	<input type="checkbox"/> 150mg PFS <input type="checkbox"/> 250mg/mL Vial <input type="checkbox"/> 125mg ClickJect Pen	<input type="checkbox"/> Starter Dose: Infuse _____ mg at weeks 0, 2, and 4 <input type="checkbox"/> Maintenance Dose: Infuse _____ mg at every 4 weeks thereafter (<60kg = 500mg, 60kg to 100kg = 750mg, and >100kg = 1000mg) <input type="checkbox"/> SC: Inject 125mg SC once a week		
Otezla	<input type="checkbox"/> 28 Day Starter Pack <input type="checkbox"/> 30mg	<input type="checkbox"/> Starter Pack: Take as Directed <input type="checkbox"/> Maintenance Dose: Take 1 Table BID		
<input type="checkbox"/> Remicade <input type="checkbox"/> Avsola <input type="checkbox"/> Inflectra <input type="checkbox"/> Renflexis	<input type="checkbox"/> 100mg Vial	<input type="checkbox"/> Starter Dose: 5mg/kg (dose _____ mg) IV at 0, 2, and 6 weeks, then every 8 weeks thereafter <input type="checkbox"/> Maintenance Dose: 5mg/kg (dose _____ mg) IV every 8 weeks IV _____ mg every _____ weeks		
Rituxan	<input type="checkbox"/> 100mg Vial	<input type="checkbox"/> Loading Dose: 1000mg IV at Day 0 and Day 15 <input type="checkbox"/> Maintenance Dose: 50mg IV at month 12 and every 6 months thereafter		
Siliq	<input type="checkbox"/> 210mg/1.5mL PFS	<input type="checkbox"/> Loading Dose: Inject 210mg SC at weeks 0,1, and 4 <input type="checkbox"/> Maintenance Dose: 210mg SC every 2 weeks thereafter	<input type="checkbox"/> Starter Dose: 3 PFS <input type="checkbox"/> Maintenance Dose 2 PFS	

Prescriber Signature: _____ DAW (Dispense as Written) Date: _____

The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intend recipient, please notify us immediately by faxing back to the originator.

DERMATOLOGY REFERRAL FORM	Y Medical Associates Fax: 855-838-0623 Phone: 800-447-7558	
Date: _____		

Patient Information	Prescriber Information
Patient Name: _____	Prescriber Name: _____
Address: _____	Address: _____
City, State, Zip: _____	City, State, Zip: _____
Home Phone: _____	Phone: _____
Cell Phone: _____	Fax: _____
DOB: _____	DEA: _____ NPI #: _____
Gender: <input type="checkbox"/> M <input type="checkbox"/> F	Contact Person: _____

Insurance Information		
Primary Insurance: _____	ID#: _____	Group: _____
Secondary Insurance: _____	ID#: _____	Group: _____
Prescription Card: _____ ID#: _____	BIN#: _____	PCN#: _____ Group: _____

Clinical Information (please fax all pertinent clinical information)	
Diagnosis: <input type="checkbox"/> L20.9 (Atopic Dermatitis) <input type="checkbox"/> L40.0 (Psoriasis Vulgaris/Plaque Psoriasis/Nummular Psoriasis) <input type="checkbox"/> L40.8 (Other Psoriasis) <input type="checkbox"/> L40.9 (Psoriasis/Unspecified) <input type="checkbox"/> L40.5 (Psoriatic Arthritis) <input type="checkbox"/> L73.2 (Hidradenitis Suppurativa) <input type="checkbox"/> M33 (Dermatopolymyositis) <input type="checkbox"/> M33.1 (Dermatomyositis) <input type="checkbox"/> L12.9 (Pemphigoid/Pemphigus) <input type="checkbox"/> L10.0 (Pemphigus Vulgaris)	
Diagnosis Date: _____ Height: _____ Weight: _____ Tb Test: <input type="checkbox"/> Yes <input type="checkbox"/> No Neg. Text Date: _____ HBV: <input type="checkbox"/> Yes <input type="checkbox"/> No If Yes, Currently Treated: <input type="checkbox"/> Yes <input type="checkbox"/> No Allergies: _____ BSA Affected (%): _____ Affected Areas: <input type="checkbox"/> Palms <input type="checkbox"/> Soles <input type="checkbox"/> Head <input type="checkbox"/> Neck <input type="checkbox"/> Genitalia <input type="checkbox"/> _____ Prior Therapy: <input type="checkbox"/> Yes <input type="checkbox"/> No Reason for Discontinuation of Therapy: _____ Approximate Start Date: _____ Approximate End Date: _____	

Prescription Information				
Medication	Dose Strength	Directions	Qty	Refills
Simponi / Simponi Aria	<input type="checkbox"/> 100mg/mL Autoinjector <input type="checkbox"/> 100mg/mL PFS <input type="checkbox"/> 50mg/mL Autoinjector <input type="checkbox"/> 50mg/mL PFS <input type="checkbox"/> 50mg/4mL Vial	<input type="checkbox"/> Inject 100mg SC once a month <input type="checkbox"/> Inject 50mg SC once a month <input type="checkbox"/> Infuse _____ mg (2mg/kg over 30 minutes at weeks 0 and 4, then every 8 weeks)	<input type="checkbox"/> 4 week supply	
Skyrizi	<input type="checkbox"/> 75mg/0.83mL (150mg dose)	<input type="checkbox"/> Initial Dose: Inject 150mg SC weeks 0, and 4 <input type="checkbox"/> Maintenance Dose: Inject 150mg SC every 12 weeks		
Stelara	<input type="checkbox"/> 45mg/0.5mL PFS <input type="checkbox"/> 90mg/1.0mL PFS	Starter Dose: <input type="checkbox"/> Inject 45mg SC (pt<100kg) on Day 1 and Day 28 <input type="checkbox"/> Inject 90mg SC (pt>100kg) on Day 1 and Day 28 Maintenance Dose: <input type="checkbox"/> Inject 45mg SC (pt<100kg) every 12 weeks thereafter <input type="checkbox"/> Inject 90mg SC (pt>100kg) every 12 weeks thereafter	<input type="checkbox"/> Initial Dose: 1 other: _____	
Taltz	<input type="checkbox"/> 80mg/mL Autoinjector	<input type="checkbox"/> Starter Dose: Inject 160mg SC at week 0, then 80mg at weeks 2, 4, 6, 8, 10, and 12 weeks <input type="checkbox"/> Maintenance Dose: Inject 80mg SC every 4 weeks		
Tremfya	<input type="checkbox"/> 100mg PFS	<input type="checkbox"/> Inject 100mg SC on weeks 0 and 4 <input type="checkbox"/> Inject 100mg SC every 8 weeks	<input type="checkbox"/> 1 Plus Refill <input type="checkbox"/> 1	
Xeljanz/XR		<input type="checkbox"/> Take 5mg PO BID <input type="checkbox"/> Take 11mg PO once daily		

Prescriber Signature: _____	DAW (Dispense as Written) Date: _____
-----------------------------	---------------------------------------

The information contained in this facsimile may be confidential and is intended solely for the use of the named recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intend recipient, please notify us immediately by faxing back to the originator.